Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile RET mutant
Therapy Zeteletinib
Indication/Tumor Type medullary thyroid carcinoma
Response Type sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
RET mutant medullary thyroid carcinoma sensitive Zeteletinib Phase I Actionable In a Phase I trial, Zeteletinib (DS-5010) treatment led to an objective response rate (ORR) of 28% (28/101), disease control rate (DCR) of 58% (59/101), median progression-free survival (mPFS) of 7.16 mo, and median duration of response (mDOR) of 11.10 mo in patients with RET-altered advanced solid tumors, with an ORR of 30% (8/27, all PR), DCR of 74% (20/27), mPFS of 12.75 mo, and mDOR of 19.15 mo in medullary thyroid cancer patients harboring a RET mutation including M918T (PMID: 40992271; NCT03780517). 40992271
PubMed Id Reference Title Details
(40992271) BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter study. Full reference...